Investor presentationJul 2026
Jul 2026 · Analysts/Institutional Investor Meet/Con. Call Updates 15 July 2026 - UniHealth held analyst/investor meeting on July 14, 2026; no presentation shared and no UPSI disclosed.
Source: Nse
Unihealth Hospitals Ltd. (UNIHEALTH)
SME CapPharma stocks · SME cap · NSE
Unihealth Hospitals Limited, formerly Unihealth Consultancy Limited, is a company whose officials participated in an analyst/investor meeting. Its registered office is in Mumbai, Maharashtra.
Data qualityFresh enough for analysisQuote updated 21 Oct, 02:01 pm ISTDetails
Quote21 Oct, 02:01 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result01 Jun, 08:21 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
65BullishSMA20 -18.1% / mo · MACD − · sector +4.4pp vs Nifty 500 (3M)
Stock trend: 43
Sector RS: 100
Sector 3M: -1.7% vs Nifty 500 -6.1%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
UNIHEALTHD candles · FIT view-3.3%TODAY · PROVISIONALLatest price ₹474.00 on 2026-10-21
Today's candle is provisional from the latest intraday quote; completed-candle scans remain unchanged.
Bar
-5.4%
RSI
27
MACD hist
-3.90
52W pos
48%
2026-10-21O ₹501.00H ₹516.95L ₹470.00C ₹474.00Vol 22,500 shIntraday candle
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
UNIHEALTHNifty PharmaNifty 500
- UNIHEALTH
- -28.7%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -23.1 pp
Chart stats
19 Oct 2026- From 52W high
- -37.6%
- 52W range position
- 54%
- ATR (14)
- 7.1%
- Volume vs 20D
- 0.30x
- Avg traded value
- ₹1.5 Cr
- 20D price channel
- ₹462 - ₹688
₹820
₹153.6 - ₹820
₹36.4
Latest completed session
20-session average
56.5% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend supports entry, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · UNDERVALUED63
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good67
Revenue +140.7% · PAT +183.3% YoY
Technical
Bullish65
Price trend and sector-relative-strength timing.
Valuation
Legacy model+36.0%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence74
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Good · 67/100Rev +141% YoY · PAT +183% YoY · operating leverage · margin compression
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹65 Cr | +140.7% | -3.0% |
| EBITDA | ₹22 Cr | NDF | -31.3% |
| Operating margin | 34.0% | NDF | -1400 bps |
| PAT | ₹17 Cr | +183.3% | -41.4% |
| PAT margin | 26.1% | NDF | -1713 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 34.90
- P/B
- 6.42
- EV/EBITDA
- 14.48
- Market Cap
- 894.00Cr
Profitability
- ROE
- 21.50%
- ROCE
- 24.50%
- ROA
- 18.11%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 38.00%
- EPS 5Y
- 39.00%
- Revenue 3Y
- 44.00%
- EPS 3Y
- 49.00%
Balance Sheet
- Debt/Equity
- 0.24
- Interest Coverage
- 27.00×
- Altman Z
- 6.71
- Book Value
- 87.60
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 3/5
- OCF
- 6.00 Cr
- EPS TTM
- 16.45
Shareholding
- Promoter Hold
- 64.82%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 61%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 132+33.3% vs prev
Net Profit
₹ CrLatest: 46.0+70.4% vs prev
Return on Equity
%Latest: 33.3+24.7% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 27.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~23.4% over last month) — short-term momentum negative.
- RSI(14) at 27 — oversold zone; bounce conditions.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 42% off 52W high · 209% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
96
RS percentile
Stage 1 Base / Transition
1M return
-24.8%
3M return
-28.7%
6M return
-1.3%
1Y return
+201.1%
RS 1D
-1
RS 20D
-2
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 11.4% below the 30-week proxy without full trend alignment.
- The 30-week proxy changed +6.1% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price above
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 322.15-4.29%
RS vs Nifty 500322
Valuation & peers
U-Score 63 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 63 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Premium Compounder
Fundamental score breakdown
U band · UNDERVALUEDValuation9/30
Growth22/25
Quality15/20
Balance Sheet9/15
Cash Flow3/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
63
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
63/100 · legacy band UNDERVALUED
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 36.0%.
- Growth contributes 22/25 to the score.
Main drags
- Valuation is weaker at 9/30; verify the latest quarterly trend.
- Cash flow is weaker at 3/10; verify the latest quarterly trend.
- Balance sheet is weaker at 9/15; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
34.9
PB
6.4
EV/EBITDA
14.5
ROE
21.5%
ROCE
24.5%
FCF Yield
—
Debt/Equity
0.2
MoS
+36.0%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
63
Previous: 62 (+1)
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+36.0%
Previous: +30.9%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
62
62
62
62
62
62
60
62
62
62
62
62
Factor attribution
Valuation
9+1
was 8
Modelled fair value
Graham Number
₹180.06
-163.2% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹740.25
+36.0% MoS
PEG
0.81
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
CHANDAN
SME
Chandan Healthcare Ltd.
Healthcare Services
match 164
58
22.2
19.8%
+50%
FAIR VALUE
GPTHEALTH
Small
GPT Healthcare Limited
Healthcare Services
match 158
70
29.5
28.5%
+41%
UNDERVALUED
SANGANI
SME
Sangani Hospitals Ltd.
Healthcare Services
match 156
29
26.2
7.8%
-20%
OVERVALUED
MAITREYA
SME
Maitreya Medicare Ltd.
Healthcare Services
match 155
12
—
-9.3%
—
OVERVALUED
GKSL
Small
Gujarat Kidney And Super Speciality Limited
Healthcare Services
match 153
36
94.8
11.1%
-95%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-10-03T07:45:45.074Z
Management commentary snapshot
Analyst/investor meeting held; no UPSI or presentation shared.
The company held an analyst meeting, but no financial or operational updates were provided as no UPSI was disclosed. Without any new information, the investment thesis remains unassessed based on this document.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare YOY
No financial or operational results were disclosed in the document to enable any comparison.
Management forward view
Analyst Meeting Outcome
Officials of the Company participated in the Analyst/investor meeting held on Tuesday, July 14, 2026. No investor presentation was shared during the meeting. No Unpublished Price Sensitive Information (UPSI) was shared during any of these interactions.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
74Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 75th percentile of the scored universe and 65th percentile within Pharma. Main check: results consistency is weak at 45/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
13 docs text-extracted · 6 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
75th percentile
overall median 67 · Pharma: 65th pctile, median 70 · SME: 93rd pctile, median 64
Evidence depth
Financial-only
13 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
55
watch · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
45
watch · quarterly consistency
Trust positives
- ▸Promoter holding is 69.5%.
- ▸Promoter pledge is zero.
- ▸ROCE is 24.5%.
Trust risks
- ▸OPM spread across recent quarters is 16%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Unihealth Hospitals Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportJul 2026
Jul 2026 · General Updates 10 July 2026 - 17th AGM on July 28, 2026; FY26 annual report, e-voting July 25-27, 2026.
Source: Nse
Annual reportJul 2026
Jul 2026 · General Updates 6 July 2026 - AGM notice/annual report proposes 12.5 lakh preferential shares at ₹520.31 to acquire 49.81% Victoria Hospital Uganda.
Source: Nse
Investor presentationJun 2026
Jun 2026 · PPT
Source: Company Ir
Concall transcriptJun 2026
Jun 2026 · Transcript
Source: Nse
Investor presentationJun 2026
Jun 2026 · Investor Presentation 3 June 2026 - Submitted H2 FY26 investor presentation after earnings call; FY26 revenue ₹137.01 Cr, PAT ₹25.83 Cr.
Source: Nse
Annual report
Annual Report 2026
Source: Nse
Concall transcriptNov 2025
Nov 2025 · Transcript
Source: Nse
Investor presentationNov 2025
Nov 2025 · PPT
Source: Nse
Investor presentationMay 2025
May 2025 · PPT
Source: Nse
Concall transcriptMay 2025
May 2025 · Transcript
Source: Nse
Annual report
Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.